12872_2017_591_MOESM2_ESM.pdf (1.07 MB)
Additional file 2: Figure S1. of Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
journal contribution
posted on 2017-06-17, 05:00 authored by Julian Halcox, José Banegas, Carine Roy, Jean Dallongeville, Guy Backer, Eliseo Guallar, Joep Perk, David Hajage, Karin Henriksson, Claudio BorghiProportion of non-statin-treated patients with markers of atherogenic dyslipidemia, according to T2DM status, CVD risk, and age: (a) according to SCORE-HDL categories; (b) according to ACC/AHA categories. Data within bars are n (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and <1.3 mmol/l in women. Abbreviations: ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglycerides (PDF 1099 kb)